Detailed clinical evaluation and personalized treatment plan.
Short answer: Orthopedic oncology deals with tumors of the musculoskeletal system — of the bone and the soft tissues around it. In adults, most malignant bone tumors are metastases (from a cancer of the breast, prostate, lung or kidney) or arise in myeloma; primary bone tumors are rarer. The essential rule: a suspicious bone lesion must not be operated on or biopsied in a hurry, by just anyone. A poorly placed biopsy can permanently compromise the chance of saving the limb. That is why evaluation, biopsy planning and staging are done together with an orthopedic surgeon experienced in oncology, within a multidisciplinary team. Reconstructive surgery rebuilds the bone and the joint after the tumor is removed — or after trauma and infections that have left large defects.
The musculoskeletal system — bones, joints, muscles, tendons — can develop tumors, like any other tissue. Most are benign: they do not spread and often need only monitoring over time. Some are malignant and behave aggressively.
In adults, the picture is different from what you find on forums, which mostly discuss tumors of children and adolescents. In adulthood, the most common cause of a malignant bone tumor is a metastasis — a cell that left a cancer of the breast, prostate, lung, kidney or thyroid and settled in the bone. Myeloma comes next. Primary bone tumors, such as chondrosarcoma, and soft-tissue sarcomas are rarer, but they exist.
The distinction matters because the treatment, the urgency and the team involved differ completely. A well-documented benign lesion may simply be monitored. A lesion suspicious for malignancy needs a precise pathway, in order, with no shortcuts.
None of the signs below automatically mean "tumor". But each deserves an evaluation, not a delay:
If this sounds like you, the first step is not surgery. It is the correct evaluation.
This is the most important thing on the page, and it is counterintuitive.
When someone discovers a suspicious bone lesion, the natural reflex — of the patient and sometimes the doctor — is "let's take a sample quickly" or "let's operate quickly". In bone oncology, misdirected haste does harm.
The biopsy — the moment a sample is taken from the lesion — is not a trivial act. The point of entry, the path of the needle, the way the tissue is handled: all must be planned so that, if the lesion is malignant, the biopsy track can later be removed at the definitive operation. A poorly placed biopsy "contaminates" healthy tissue and can turn a salvageable limb into one that can no longer be saved.
This is not an opinion. A landmark study by the Musculoskeletal Tumor Society showed that errors, complications and changes in outcome were 2 to 12 times more frequent when the biopsy was done outside the center that would treat the patient; some of those patients ended up with amputations that could have been avoided (Mankin et al., JBJS, 1996).
Hence a simple rule: a suspicious bone lesion is evaluated and biopsied by — or in direct coordination with — the surgeon who will perform the operation, within the oncology team. Not "by someone, quickly".
My role in the pathway: the orthopedic evaluation, planning and performing the surgical part — removing the tumor and reconstructing — and coordinating with the other specialists.
For benign tumors, options range from simple monitoring over time, to curettage (scraping out the lesion) or excision, when size, location or fracture risk require it.
For malignant tumors, treatment is almost always combined. Surgery means resection "with a margin" — the tumor is removed together with a margin of healthy tissue around it, so no cells remain. Depending on the type, chemotherapy or radiotherapy is added before or after surgery, decided by the oncologist and radiation oncologist. For bone metastases, the goal is often pain control, preventing or treating a fracture, and preserving function — with osteosynthesis or a prosthesis, in coordination with the oncologist.
An honest word about outcomes: in oncology there are no guarantees. There is a correct pathway, done in time, which gives you the best real chances. That is what we aim for.
Removing the tumor is half the operation. The other half is what you put in its place.
When a portion of bone or a joint is removed, a defect remains that must be reconstructed so you can use the limb again. This is where reconstruction comes in: tumor endoprostheses — special, larger prostheses that replace the removed segment —, bone grafts, and biological techniques that help the bone rebuild. The modern goal, whenever it is oncologically safe, is limb salvage, not amputation.
Reconstruction is not only for tumors. The same principles apply to:
I know the bone-regeneration side from research too: my doctoral thesis was on biologically augmented bone healing — how we can help bone rebuild better. What I studied meets, here, what I operate on.
Most bone-oncology cases in Romania are concentrated in a few large centers, in Bucharest, Cluj or Iași. There is logic to that — it is a super-specialty. But it also means a patient from Oltenia, with a suspicious bone lesion, often ends up not knowing where to go first, navigating alone between investigations and cities.
The role I take on here is that of a competent gateway, close to you: to evaluate correctly, to plan the biopsy so that no doors are closed, to coordinate the team and to do the surgical and reconstructive part — without you setting off into the unknown from day one. Where a case calls for transfer to a center with particular resources, I tell you directly and refer you. Being honest about what is done here and what is done better elsewhere is part of the job.
I am Dr. Alexandru Florian Grecu, senior specialist in orthopedics and traumatology, with clinical activity in Craiova, and Senior Lecturer at the University of Medicine and Pharmacy of Craiova. Beyond arthroplasty and arthroscopy, I work in the oncologic and reconstructive side of orthopedics — evaluating bone tumors, resection surgery and reconstruction of defects, in coordination with the multidisciplinary team. My doctoral thesis was on biologically augmented bone healing. For details about my training, see the About page.
If you have chronic pain and are considering surgery, the first consultation commits you to nothing. We look together at your X-rays, the clinical examination and the non-surgical and surgical options. The decision stays yours.
Appointments: 0251 960
Detailed clinical evaluation and personalized treatment plan.
Mankin HJ, Mankin CJ, Simon MA. — The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am. 1996;78(5):656–663.
Staging and treatment follow the principles of the international musculoskeletal tumor surgery societies (MSTS) and the European oncology guidelines (ESMO) for bone and soft-tissue sarcomas.